These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 1353938)

  • 1. Regulation of GTP biosynthesis.
    Weber G; Nakamura H; Natsumeda Y; Szekeres T; Nagai M
    Adv Enzyme Regul; 1992; 32():57-69. PubMed ID: 1353938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reciprocal alterations of GMP reductase and IMP dehydrogenase activities during differentiation in HL-60 leukemia cells.
    Nakamura H; Natsumeda Y; Nagai M; Takahara J; Irino S; Weber G
    Leuk Res; 1992; 16(6-7):561-4. PubMed ID: 1353130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targets and markers of selective action of tiazofurin.
    Weber G; Natsumeda Y; Pillwein K
    Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
    Jayaram HN; Cooney DA; Grusch M; Krupitza G
    Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics of purine nucleotide metabolism and GMP-reductase activity in chicken tissues].
    Kokunin VA; Kotsiuruba AV; Tarakanov SS; Kostychev IuN
    Ukr Biokhim Zh (1978); 1987; 59(4):47-52. PubMed ID: 2820099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mycobacterial guaB1 gene encodes a guanosine 5'-monophosphate reductase with a cystathionine-β-synthase domain.
    Knejzlík Z; Doležal M; Herkommerová K; Clarova K; Klíma M; Dedola M; Zborníková E; Rejman D; Pichová I
    FEBS J; 2022 Sep; 289(18):5571-5598. PubMed ID: 35338694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
    Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
    Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical issues in chemotherapy with tiazofurin.
    Weber G
    Adv Enzyme Regul; 1989; 29():75-95. PubMed ID: 2699155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of purine salvage in circumventing the action of antimetabolites in rat hepatoma cells.
    Natsumeda Y; Ikegami T; Olah E; Weber G
    Cancer Res; 1989 Jan; 49(1):88-92. PubMed ID: 2461800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct assay method for guanosine 5'-monophosphate reductase activity.
    Nakamura H; Natsumeda Y; Nagai M; Shiotani T; Weber G
    Anal Biochem; 1992 Oct; 206(1):115-8. PubMed ID: 1333733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines.
    Szekeres T; Schuchter K; Chiba P; Ressmann G; Lhotka C; Gharehbaghi K; Szalay SM; Pillwein K
    Biochem Pharmacol; 1993 Dec; 46(11):1903-7. PubMed ID: 7903533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
    Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
    J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cystathionine-β-synthase domains on the guanosine 5''-monophosphate reductase and inosine 5'-monophosphate dehydrogenase enzymes from Leishmania regulate enzymatic activity in response to guanylate and adenylate nucleotide levels.
    Smith S; Boitz J; Chidambaram ES; Chatterjee A; Ait-Tihyaty M; Ullman B; Jardim A
    Mol Microbiol; 2016 Jun; 100(5):824-40. PubMed ID: 26853689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
    Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
    Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiazofurin: molecular and clinical action.
    Weber G; Prajda N; Abonyi M; Look KY; Tricot G
    Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
    Szekeres T; Fritzer M; Pillwein K; Felzmann T; Chiba P
    Life Sci; 1992; 51(16):1309-15. PubMed ID: 1357518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of resistance to tiazofurin in hepatoma 3924A.
    Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
    Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
    Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
    Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of de novo and salvage pathways in chemotherapy.
    Weber G; Nagai M; Natsumeda Y; Ichikawa S; Nakamura H; Eble JN; Jayaram HN; Zhen WN; Paulik E; Hoffman R
    Adv Enzyme Regul; 1991; 31():45-67. PubMed ID: 1877399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.